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Summary. Background: Low levels of activated protein C
(APC) are a risk factor for venous thrombosis. Themechanisms
leading to interindividual differences in APC are not totally
elucidated. Protein C is activated by the thrombin–thrombo-
modulin complex. As thrombin binds to fibrinogen and
thrombomodulin through a common region, it is conceivable
that fibrinogen influences the activation of protein C. This
would help to explain the association between high levels of
fibrinogen and an increased thrombotic risk. Methods: We
analyzed the association between circulating APC levels and
fibrinogen concentration in 382 healthy subjects. Subsequently,
we studied the effect of increasing fibrinogen concentrations on
the APC generation on cultured endothelial cells. Results: An
independent inverse association between circulating APC levels
and fibrinogen was found [b coefficient, )0.16; 95% confidence
interval (95% CI) )0.26, )0.06; P ¼ 0.001]. For each
100 mg dL)1 increase in fibrinogen, the independent risk of
having lowAPC levels (<0.7 ng mL)1) was almost three times
higher (OR 2.8; 95% CI 1.1, 7.2; P ¼ 0.04). Accordingly, a
notable association between increasing fibrinogen concentra-
tions and the reduction in the thrombin–thrombomodulin
dependent activation of protein C on endothelial cells was
found (r ¼ )0.57; P ¼ 0.002). Conclusions: We present evi-
dence of an inverse association between circulating APC and
fibrinogen levels. According to this finding together with the
results of our in vitro experiments, we propose that the
impairment in the generation of APC on endothelial cells
constitutes a new prothrombotic mechanism of fibrinogen.
Keywords: endothelial cell, fibrinogen, hypercoagulability,
protein C, thrombosis.
Introduction
Activated protein C (APC) is a major regulatory protein of the
coagulation cascade. Protein C, the zymogen of APC, is
activated by thrombin bound to thrombomodulin on cell
surfaces. The activation is more efficient in the presence of the
endothelial protein C/APC receptor (EPCR). APC, in concert
with its cofactor protein S, exerts its anticoagulant function by
cleaving activated factors V and VIII [1]. Low circulating levels
of APC constitute a risk factor for venous thrombosis [2,3].
Although several reasons have been proposed to explain the
origin of these low APC levels (i.e. low zymogen level,
polymorphisms in the EPCR gene [4,5]), the underlying
mechanisms by which circulating APC levels differ among
individuals are not totally understood. In the search for new
mechanisms explaining these differences, a direct involvement
of fibrinogen is conceivable: it must be noted that thrombin
binds to fibrinogen and thrombomodulin through a common
region termed the anion-binding exosite-1 [6–8]. Therefore,
fibrinogen could prevent the formation of the thrombin–
thrombomodulin complexes, thus impairing the generation
of APC. This mechanism could explain to some extent
the association of high fibrinogen levels with thrombotic risk
[9–12].
To test this hypothesis, we investigated the relationship
between fibrinogen and APC levels in a group of healthy
subjects and subsequently tested the ability of fibrinogen to
influence the activation of protein C in cultured endothelial
cells. We found an independent association between fibrinogen
and circulating APC levels and accordingly, we found that
increasing concentrations of fibrinogen were able to impair the
generation of APC in endothelial cell cultures.We propose that
fibrinogen plays a prothrombotic role by influencing the
circulating APC levels.
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Methods
Participants
Four-hundred and one subjects without thrombosis constitu-
ting the control group of a case–control study carried out to
evaluate the role ofAPC in venous thrombosis were included in
the study [5]. Plasma samples from 19 subjects were not
available for fibrinogen determination, so finally 382 were
studied (Table 1). The study was approved by the Ethics
Committee. Informed consent was obtained from all partici-
pants.
Measurement of plasma fibrinogen levels
Fibrinogen concentration was determined in plasma using
high-sensitivity standard reagent IL (Instrumentation Labor-
atory, Milan, Italy) on a ACL 7000 autoanalyzer (Instrumen-
tation Laboratory).
Measurement of plasma APC levels
Levels of circulating APC were determined by a previously
reported modification [2] of a method based on enzyme-linked
immunosorbent assay (ELISA) detection of the APC com-
plexed to its major plasma inhibitor, protein C inhibitor (PCI)
[4]. 4.5 mL of fasting blood was drawn into two tubes
containing 0.5 mL of 0.129 M trisodium citrate. Immediately
after extraction 46 lL of 1000 U mL)1 heparin (Roger,
Madrid, Spain) was added to one tube and the mixture was
incubated at 37 C for 30 min to force all circulating APC to
form complexes with plasma PCI. More than 95% of the APC
forms complexes with PCI under these conditions. Therefore,
the concentration of APC:PCI in the tube with heparin is the
sum of in vivo circulating APC:PCI complexes and the com-
plexes formed in vitro from the circulating APC. To the second
blood tube was added 46 lL of a mixture of 0.58 M benzami-
dine.HCl (Sigma, St Louis, MO, USA) and 0.5 mM PPACK
(Calbiochem, La Jolla, CA, USA) to immediately inhibit
circulating APC. By doing this, the formation of newAPC:PCI
complexes was prevented and the APC:PCI complexes in this
tube would reflect the concentration of the in vivo circulating
APC:PCI complexes. Hence, circulating APC concentration
could be calculated from the difference in APC:PCI concen-
tration in the two samples. The intra- and inter-assay variation
coefficients were not higher than 5% and 8%, respectively. All
samples were tested in duplicate for both conditions. APC
determination was performed within 6 months after sampling.
Other laboratory measurements
C-reactive protein (CRP) was measured by a high-sensitivity
nephelometric assay (Behringwerke AG, Marburg, Germany).
Protein C, soluble endothelial protein C receptor (sEPCR)
levels, and the polymorphism 4678G/C of the EPCR gene were
measured as described in previous studies [2,5].
Effect of fibrinogen on APC generation
The experiment was based on previous procedures [13]: 50 000
EA.hy926 cells (endothelium-derived cell line expressing
thrombomodulin and EPCR [14], kindly supplied by Dr C.J.
Edgell, University of North Carolina, NC, USA) were
incubated with 0.4 nM thrombin (ERL, Swansea, UK) in a
20 mM Tris buffer, pH 7.4, with 150 mM NaCl, 5 mM CaCl2,
0.6 mM MgCl2, 1% BSA, 0.01% Tween-20 and 0.02% NaN3.
After 15 min, the cells were washed once and 60 nM protein C
(kindly supplied by Lilly, Indianapolis, IN, USA) was added in
the presence of increasing concentrations of fibrinogen (ERL).
After 30 min 0.2 lM lepirudin (ScheringAG, Berlin, Germany)
was added, together with 0.4 mM S-2366 (Chromogenix,
Milan, Italy), whose proteolysis by APC was monitored in a
Table 1 Baseline characteristics of the healthy group, overall and stratified by tertiles according to fibrinogen levels
Overall (n ¼ 382)
Fibrinogen concentration
115–231 mg dL)1
(n ¼ 127)
232–273 mg dL)1
(n ¼ 130)
274–430 mg dL)1
(n ¼ 125)
Age (years) 41.5 ± 13.1 37.6 ± 12.3 42.6 ± 12.5 44.4 ± 13.6
Sex, females (%) 191 (50) 65 (51) 59 (45) 67 (54)
Fibrinogen (mg dL)1) 252 ± 44 205 ± 21 253 ± 12 300 ± 26
APC (ng mL)1) 1.28 ± 0.47 1.44 ± 0.50 1.25 ± 0.44 1.15 ± 0.41
APC:PCI (ng mL)1) 0.55 ± 0.31 0.59 ± 0.34 0.53 ± 0.24 0.49 ± 0.32
Protein C (%) 102 ± 18 104 ± 19 102 ± 18 101 ± 14
PCI (%) 101 ± 22 99 ± 19 102 ± 23 101 ± 21
sEPCR (ng mL)1) 123 ± 73 127 ± 77 115 ± 64 127 ± 78
EPCR 4678G/C
GG (%) 105 (27) 34 (27) 33 (25) 38 (30)
GC (%) 197 (52) 58 (46) 70 (54) 69 (55)
CC (%) 80 (21) 35 (27) 27 (21) 18 (15)
C-reactive protein (mg L)1) 1.38 ± 0.97 1.19 ± 0.99 1.35 ± 0.84 1.60 ± 1.04
Values given are mean ± SD.
APC, activated protein C; PCI, protein C inhibitor; EPCR, endothelial protein C/APC receptor.
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iEMS Reader (Labsystems, Helsinki, Finland). The experi-
ments were performed in triplicate. This method was also used
to assess the effect of 495 mg dL)1 (15 lM) fibrinogen on the
kinetics of the protein C activation. Under the conditions used,
no formation of clots took place along the experiment. The
data curve fitting the Michaelis–Menten equations was per-
formed using Enzfitter software (Biosoft, Cambridge, UK).
Statistical methods
We compared APC levels between subjects at higher and lower
fibrinogen concentrations with a Mann–Whitney test. A linear
regression model was used to assess the relationship between
different variables with APC levels. Fibrinogen, the main
independent variable, was considered both as a continuous
variable and as a categorical variable (tertiles). After running a
univariate linear model, a multiple linear regression model was
computed including the variables that could be confounding
factors. The risk [expressed as odds ratios (OR)] of having low
APC levels was modeled using a logistic regression analysis in
which the outcome (dependent) variable was low vs. medium/
high levels of APC, and the independent variables were the
same as for the multivariate linear regression model.
The relationship between fibrinogen and APC in vitro was
assessed using the Pearson correlation coefficient and a linear
regression analysis.
Results
Relationship between fibrinogen and APC levels in healthy
subjects
We analyzed the relationship between fibrinogen and circula-
tingAPC levels in 382 healthy subjects (Table 1).When a linear
regression analysis adjusting for age, sex and factors which
were shown to influence APC levels in the univariate analysis
(CRP, protein C, and the EPCR 4678G/C polymorphism) was
performed, an inverse, independent correlation was seen
between fibrinogen and APC levels [b coefficient, )0.16; 95%
confidence interval (95% CI) )0.26, )0.06; P ¼ 0.001]. The
APC–PCI complexes present in blood at the time of blood
collection, which reflects APC generation in vivo already
inhibited by PCI displayed a similar inverse correlation with
fibrinogen levels (b coefficient, )0.13; 95% CI )0.16, )0.02;
P ¼ 0.011).
Subsequently, we categorized the population in tertiles
according to fibrinogen values (Table 1), and performed a
multivariate logistic regression analysis taking low APC levels
(under 0.7 ng mL)1, shown to be a risk factor for venous
thrombosis [2]) as the dependent variable. Again, the subjects in
the highest fibrinogen tertile were at higher risk of having low
APC levels than the subjects of the low fibrinogen group (OR
3.0; 95% CI 1.0, 9.2; P ¼ 0.06). This effect could be also seen
when taking fibrinogen as a continuous variable: for each
100 mg dL)1 increase in fibrinogen, the independent risk of
having low APC levels was almost threefold higher (OR 2.8;
95%CI 1.1, 7.2; P ¼ 0.04). Hence, for the first time we present
evidence that high levels of fibrinogen are independently related
to low APC levels. Among the other factors studied, CRP, the
genotype CC of the G4678C polymorphism of the EPCR gene
and, more weakly, protein C were also independently associ-
ated with APC levels (not shown), although only protein C was
independently associated with low APC levels [for each 1%
increase in protein C, the risk of having low APC levels
decreased (OR 0.9; 95% CI 0.8, 1.0; P < 0.001)]. PCI
concentrations were essentially equal in the three groups and
therefore did not explain the differences in the APC circulating
levels.
Effect of fibrinogen on the activation of protein C
In the search for a molecular mechanism, which conforms with
the inverse association between fibrinogen and APC levels
observed, we studied the effect of fibrinogen on the thrombin-
dependent APC generation on endothelial cells. Consistently
with our findings, we found that increasing concentrations of
fibrinogen dose-dependently reduced the activation of protein
C on the surface of EA.hy926 cells (Fig. 1A): an inverse
correlation was seen between fibrinogen and the initial rate of
protein C activation (r ¼ )0.57; P ¼ 0.002). Interestingly, this
finding was obtained using protein C at the physiological
concentration and fibrinogen at a broad range of concentra-
tions covering low and high levels resembling frequent clinical
situations [9–12]. Therefore, these observations are coherent
with the inverse association between circulating fibrinogen and
APC levels observed in a group of healthy subjects. To better
understand the nature of the effect of fibrinogen on the
generation of APC, the effect of 495 mg dL)1 (15 lM)
fibrinogen on the kinetics of protein C activation was analyzed
(Fig. 1B). The apparent Michaelis–Menten constant of the
protein C activation was similar in the presence and in the
absence of fibrinogen while the Vmax was lower when
fibrinogen was present. This is coherent with a hampered
binding of thrombin to thrombomodulin in the presence of
fibrinogen.
Discussion
Low levels of circulating APC are considered a risk factor for
venous thrombosis [2,3]. Although factors like the concentra-
tion of zymogen (protein C), the basal levels of thrombin
(indirectly assessed by the measurement of F1 + 2 levels) or
several polymorphisms in the EPCR gene can partly explain
the different APC levels found among individuals [4,5], they are
not enough to account for all the interindividual variability. In
the search for new mechanisms contributing to influence APC
levels, we wanted to explore if fibrinogen could play a role: high
levels of fibrinogen have been associated with arterial and
venous thrombosis [9–12]. However, they have been considered
a disease marker rather than a causal agent [15–17]. Recently,
some evidence linking them to a higher fibrin deposition in
transgenic mice has been presented but the mechanism by
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which high fibrinogen levels are associated with higher
thrombotic risk is not completely understood [18].
For the first time, we provide evidence that high fibrinogen
levels are involved in impairing APC generation. First, we
demonstrated that the variations in the concentration of
fibrinogen in a group of healthy subjects are independently and
inversely associated with the circulating APC levels. It is worth
noting that this association was independent of the inflamma-
tory status, estimated by the CRP level. Furthermore, we
believe that by studying a group of healthy subjects we are
underestimating the extent of the association, as it is not
unusual to find patients exhibiting fibrinogen levels well
above the highest concentration analyzed in our study
(i.e. thrombosis, atherosclerosis, autoimmune diseases and
sepsis) [9–12,19,20]. Secondly, to exclude the possibility that
plasmatic fibrinogen does not influence the circulating APC
levels but is an innocent bystander, we performed experiments
of thrombin-dependent activation of protein C on endothelial
cells. We could demonstrate that increasing levels of fibrinogen
were able to reduce the initial rate of APC generation. The
effect increased linearly with the fibrinogen concentration.
These results, which conform with the findings obtained in the
population studied, are also coherent with previous observa-
tions in which fibrinogen was shown to hamper protein C
activation by competitively inhibiting the binding of thrombin
to thrombomodulin in solution [21]. Nevertheless, the present
study is the first one reporting this effect of fibrinogen using
cell-anchored thrombomodulin. The fact that fibrinogen did
not modify the apparent Km but the Vmax of the APC
generation is consistent with the notion that fibrinogen, by
binding thrombin, reduced the number of thrombin–throm-
bomodulin complexes available to activate protein C on the
endothelial surface. This mechanism is plausible as thrombo-
modulin and fibrinogen share a common binding site on
thrombin (i.e. anion binding exosite-1) [8], but could it account
for the association between high fibrinogen concentrations and
low APC levels in humans? The answer would be that it could.
Huge amounts of fibrinogen are needed for it to play a
competitive role, as the affinity of thrombomodulin for
thrombin, in the nanomolar range, is much higher than the
affinity of fibrinogen for thrombin (in the micromolar range).
However, there is indeed a huge excess of fibrinogen as
compared with thrombomodulin in vivo: assuming that the
thrombomodulin concentration is around 0.15 nM in major
vessels and 500 nM in the microcirculation [22], there is at least
a 20 000-fold excess of fibrinogen over thrombomodulin in
major vessels and a sixfold excess in the microcirculation.
Under these conditions, variations in the plasmatic concentra-
tion of fibrinogen could be relevant for the formation of
thrombin–thrombomodulin complexes and the subsequent
rate of activation of protein C, especially in the major
vasculature.
Thus we conclude that plasmatic fibrinogen and APC levels
are inversely associated, and provide a mechanism which
suggests that there is a cause–effect relationship. The fibrin-
ogen concentration could be involved in the modulation of
protein C activation. As low circulating APC levels are
associated with an increased risk of thrombosis [2,3], we
propose that elevated concentrations of fibrinogen may
increase the thrombotic risk at least partly by decreasing
APC generation.
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Fig. 1. Effect of fibrinogen on the activation of protein C by thrombin on
the endothelial surface. (A) 0.4 nM thrombin and 60 nM protein C were
added to EA.hy926 cells (50 000 well)1) in the presence of increasing
concentrations of fibrinogen, and the generation of activated protein C
(APC) was monitored at 405 nm. For each condition, the
mean ± standard deviation of three experiments is represented. The
correlation between the fibrinogen concentration and the initial rate of
protein C activation is shown. (B) The kinetic parameters of the activation
of protein C by thrombin were calculated in the absence or the presence of
495 mg dL)1 (15 lM) fibrinogen under the same conditions described in
panel A. The Lineweaver–Burk plot in the inset shows that the Michaelis–
Menten constant (Km) was similar in the presence (75.8 nM) or absence
(76.9 nM) of fibrinogen while theVmax decreased from 2.45 mAU min
)1 in
its absence to 1.76 mAU min)1 in its presence. The experiment was
repeated twice more with similar results. Solid circles, activation in the
absence of fibrinogen; open circles, activation in the presence of
495 mg dL)1 (15 lM) fibrinogen.
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